Home/Filings/4/0001209191-19-045960
4//SEC Filing

Boissel Stephane 4

Accession 0001209191-19-045960

CIK 0001001233other

Filed

Aug 13, 8:00 PM ET

Accepted

Aug 14, 5:04 PM ET

Size

9.5 KB

Accession

0001209191-19-045960

Insider Transaction Report

Form 4
Period: 2018-11-27
Boissel Stephane
EVP, Corporate Strategy
Transactions
  • Other

    Free Shares Call Options (obligation to sell to Issuer)

    2018-11-2744 total
    From: 2019-05-03Exp: 2020-12-02Common Stock
  • Other

    Free Shares Put Options (right to sell to Issuer)

    2018-11-27+44 total
    From: 2019-07-04Exp: 2021-02-03Common Stock
Footnotes (2)
  • [F1]In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person granted to the Issuer the right to purchase up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning May 3, 2019 (the "Free Shares Call Options"). The exercise price per Subject Free Share to be paid by the Issuer upon exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329.
  • [F2]In connection with the acquisition by the Issuer of Sangamo France, in addition to the grant to the Issuer of the Free Shares Call Options, the Reporting Person was granted the right to sell to the Issuer the Subject Free Shares for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"), which Free Shares Put Options shall be exercisable to the extent that the corresponding Free Shares Call Options are not exercised by the Issuer. The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of his exercise of his Free Shares Put Options (as converted to euros) divided by 12.8329.

Issuer

SANGAMO THERAPEUTICS, INC

CIK 0001001233

Entity typeother

Related Parties

1
  • filerCIK 0001755198

Filing Metadata

Form type
4
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 5:04 PM ET
Size
9.5 KB